OSE Immunotherapeutics – Key opinion leader webinar with Dr Stephen Liu and Professor Benjamin Besse

In this webinar, OSE Immunotherapeutics joins key opinion leaders Dr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center (Washington DC, United States) and Professor Benjamin Besse, medical oncologist and director of clinical research at the Gustave Roussy Institute (Villejuif, France), to discuss the current unmet needs in lung cancer therapeutics and the development landscape of OSE’s cancer vaccine, Tedopi.

About OSE Immunotherapeutics

OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immuno-oncology and immuno-inflammation. At the forefront of its portfolio is Tedopi, a novel off-the shelf cancer vaccine that has previously demonstrated promising outcomes in a Phase III study (Atalante-1) involving advanced non-small cell lung cancer patients who had progressed on first-line treatment with chemotherapy and immune checkpoint inhibitors. OSE is now focused on the confirmatory pivotal Phase III ARTEMIA trial, aiming to build on prior results by evaluating Tedopi specifically in patients with secondary resistance to checkpoint inhibitors. ARTEMIA is due to commence in mid-2024. The company’s R&D pipeline is robust and diverse, ensuring that its progress remains resilient and independent of any singular subsector.